Cover Image
市場調查報告書

腓骨肌萎縮症 - 開發中產品分析

Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321933
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
腓骨肌萎縮症 - 開發中產品分析 Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 60 Pages
簡介

腓骨肌萎縮症是遺傳性疾病,會出現四肢末梢神經損傷造成的肌肉無力,頻繁搖搖晃晃和跌倒,無法行走等症狀。

本報告提供腓骨肌萎縮症治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

腓骨肌萎縮症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Addex Therapeutics Ltd.
  • Genzyme Corporation
  • PharmatrophiX, Inc.
  • Pharnext SAS

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (baclofen + naltrexone + sorbitol)
  • ADX-71441
  • Small Molecule to Inhibit Rab7 GTPase for Oncology, Neuropathy, Immunology, Neurodegenerative Diseases, Lipidoses and Charcot-Marie-Tooth Disease Type II
  • Small Molecules to Agonize TrkB and TrkC for Alzheimer's, Parkinson's and Charcot-Marie-Tooth Disease
  • Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders
  • Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A
  • Stem Cell Therapy to Activate PMP22 for Charcot-Marie-Tooth Disease Type 1A

最新的開發平台資訊

開發暫停中的計劃

產品開發的里程碑

  • 熱門的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8265IDB

Summary

Global Markets Direct's, 'Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016', provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease
  • The report reviews pipeline therapeutics for Charcot-Marie-Tooth Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Charcot-Marie-Tooth Disease therapeutics and enlists all their major and minor projects
  • The report assesses Charcot-Marie-Tooth Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Charcot-Marie-Tooth Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Charcot-Marie-Tooth Disease Overview
  • Therapeutics Development
    • Pipeline Products for Charcot-Marie-Tooth Disease - Overview
    • Pipeline Products for Charcot-Marie-Tooth Disease - Comparative Analysis
  • Charcot-Marie-Tooth Disease - Therapeutics under Development by Companies
  • Charcot-Marie-Tooth Disease - Therapeutics under Investigation by Universities/Institutes
  • Charcot-Marie-Tooth Disease - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Charcot-Marie-Tooth Disease - Products under Development by Companies
  • Charcot-Marie-Tooth Disease - Products under Investigation by Universities/Institutes
  • Charcot-Marie-Tooth Disease - Companies Involved in Therapeutics Development
    • Acetylon Pharmaceuticals, Inc.
    • Addex Therapeutics Ltd
    • Affectis Pharmaceuticals AG
    • Genzyme Corporation
    • InFlectis BioScience
    • Lead Discovery Center GmbH
    • PharmatrophiX, Inc.
    • Pharnext SAS
  • Charcot-Marie-Tooth Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (baclofen + naltrexone + sorbitol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AFC-5128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFB-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22B10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Rab7 GTPase for Oncology, Neuropathy, Immunology, Neurodegenerative Diseases, Lipidoses and Charcot-Marie-Tooth Disease Type II - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Charcot-Marie-Tooth Disease Type I A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate PMP22 for Charcot-Marie-Tooth Disease Type 1A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Charcot-Marie-Tooth Disease - Dormant Projects
  • Charcot-Marie-Tooth Disease - Product Development Milestones
    • Featured News & Press Releases
      • Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A
      • Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments
      • Jan 25, 2016: IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease
      • Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A
      • Oct 27, 2015: FDA grants orphan drug designation to IFB-088 (Sephin1) for the treatment of Charcot-Marie-Tooth disease
      • Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting
      • Jan 13, 2015: InFlectis BioScience banks €1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases
      • Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications
      • Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder
      • Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A
      • Oct 03, 2013: Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease
      • Apr 24, 2013: Addex Receives Approval To Initiate Phase I First-In-man Clinical Study For ADX71441
      • Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441
      • Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease
      • Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Charcot-Marie-Tooth Disease, H2 2016
  • Number of Products under Development for Charcot-Marie-Tooth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Affectis Pharmaceuticals AG, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Genzyme Corporation, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by InFlectis BioScience, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by PharmatrophiX, Inc., H2 2016
  • Charcot-Marie-Tooth Disease - Pipeline by Pharnext SAS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Charcot-Marie-Tooth Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Charcot-Marie-Tooth Disease, H2 2016
  • Number of Products under Development for Charcot-Marie-Tooth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top